Aktie A2JD8X VAXART, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Vaxart, Inc.

Aktien

A2JD8X

US92243A2006

VXRT

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 22.04.2024 		% 5 Tage % 1. Jan.
0.7625 USD +0.91% Intraday Chart für Vaxart, Inc. -16.13% +33.12%
14.03. Vaxart, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
14.03. Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
Vaxart Appoints Steven Lo as Chief Executive; Shares Fall
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
Vaxart, Inc. Announces Chief Executive Officer Changes
Vaxart, Inc. Announces Management Appointments
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
North American Morning Briefing : Stock Futures -2-
Vaxart Secures $9.3 Million Award for Phase 2b COVID-19 Pill Study
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Vaxart to Raise $10 Million From RA Capital Management; Shares Rise
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
Vaxart, Inc. Announces Management Change
Vaxart, Inc. Announces CEO Changes
Vaxart, Inc. Announces Resignation of Andrei Floroiu as President and Director
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2JD8X Aktie
  4. Nachrichten Vaxart, Inc.
  5. Andere Sprachen